Previous close | 51.34 |
Open | 51.22 |
Bid | 50.39 x 900 |
Ask | 50.40 x 1200 |
Day's range | 50.26 - 51.42 |
52-week range | 38.48 - 61.71 |
Volume | |
Avg. volume | 28,272,935 |
Market cap | 283.575B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 13.11 |
EPS (TTM) | 3.85 |
Earnings date | 26 Jul 2022 - 01 Aug 2022 |
Forward dividend & yield | 1.60 (3.12%) |
Ex-dividend date | 12 May 2022 |
1y target est | 59.33 |
Citi shares popped after Berkshire Hathaway announced it had acquired 55 million shares of the company, the FDA approved Pfizer's COVID booster for ages 5-11, and JD.com topped Q1 sales estimates despite China lockdowns.
For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.